UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 149

Sortiert nach

Carfilzomib-dexamethasone vs bortezomib-dexamethasone in relapsed or refractory multiple myeloma by cytogenetic risk in the phase 3 study ENDEAVOR

Leukemia, 2017-06, Vol.31 (6), p.1368-1374

2017

Link zum Volltext

Verfügbarkeit prüfen

Prognostic value of antigen expression in multiple myeloma: a PETHEMA/GEM study on 1265 patients enrolled in four consecutive clinical trials

Leukemia, 2018-04, Vol.32 (4), p.971-978

2018

Link zum Volltext

Verfügbarkeit prüfen

Impact of prior treatment on patients with relapsed multiple myeloma treated with carfilzomib and dexamethasone vs bortezomib and dexamethasone in the phase 3 ENDEAVOR study

Leukemia, 2017-01, Vol.31 (1), p.115-122

2017

Link zum Volltext

Verfügbarkeit prüfen

Bortezomib and thalidomide maintenance after stem cell transplantation for multiple myeloma: a PETHEMA/GEM trial

Leukemia, 2017-09, Vol.31 (9), p.1922-1927

2017

Link zum Volltext

Verfügbarkeit prüfen

Analytical and clinical validation of a novel in-house deep-sequencing method for minimal residual disease monitoring in a phase II trial for multiple myeloma

Leukemia, 2017-06, Vol.31 (6), p.1446-1449

2017

Link zum Volltext

Verfügbarkeit prüfen

Pathogenesis and treatment of renal failure in multiple myeloma

Leukemia, 2008-08, Vol.22 (8), p.1485-1493

2008

Link zum Volltext

Verfügbarkeit prüfen

Pathogenesis and progression of monoclonal gammopathy of undetermined significance

Leukemia, 2008-09, Vol.22 (9), p.1651-1657

2008

Link zum Volltext

Verfügbarkeit prüfen

Pattern of relapse and progression after autologous SCT as upfront treatment for multiple myeloma

Bone marrow transplantation (Basingstoke), 2014-02, Vol.49 (2), p.223-227

2014

Link zum Volltext

Verfügbarkeit prüfen

Absence of spontaneous response improvement beyond day +100 after autologous stem cell transplantation in multiple myeloma

Bone marrow transplantation (Basingstoke), 2017-04, Vol.52 (4), p.567-569

2017

Link zum Volltext

Verfügbarkeit prüfen

Clinical significance of CD81 expression by clonal plasma cells in high-risk smoldering and symptomatic multiple myeloma patients

Leukemia, 2012-08, Vol.26 (8), p.1862-1869

2012

Link zum Volltext

Verfügbarkeit prüfen

At-home autologous stem cell transplantation in multiple myeloma with and without G-CSF administration: a comparative study

Bone marrow transplantation (Basingstoke), 2016-04, Vol.51 (4), p.593-595

2016

Link zum Volltext

Verfügbarkeit prüfen

Allogeneic hematopoietic SCT in multiple myeloma: long-term results from a single institution

Bone marrow transplantation (Basingstoke), 2015-05, Vol.50 (5), p.658-662

2015

Link zum Volltext

Verfügbarkeit prüfen

Carfilzomib-lenalidomide-dexamethasone vs lenalidomide-dexamethasone in relapsed multiple myeloma by previous treatment

Blood cancer journal (New York), 2017-04, Vol.7 (4), p.e554-e554

2017

Link zum Volltext

Verfügbarkeit prüfen

Prognostic factors for multiple myeloma in the era of novel agents

Annals of oncology, 2008-09, Vol.19 (suppl-7), p.vii117-vii120

2008

Link zum Volltext

Verfügbarkeit prüfen

Diagnosis, treatment, and response assessment in solitary plasmacytoma: updated recommendations from a European Expert Panel

Journal of hematology and oncology, 2018-01, Vol.11 (1), p.10-10, Article 10

2018

Link zum Volltext

Verfügbarkeit prüfen

Serial intestinal endoscopic examinations of patients with persistent diarrhea after allo-SCT

Bone marrow transplantation (Basingstoke), 2012-05, Vol.47 (5), p.694-699

2012

Link zum Volltext

Verfügbarkeit prüfen

P898: COMPARISON OF TECLISTAMAB WITH BELANTAMAB MAFODOTIN IN PATIENTS WITH TRIPLE‐CLASS EXPOSED RELAPSED/REFRACTORY MULTIPLE MYELOMA USING MATCHING‐ADJUSTED INDIRECT TREATMENT COMPARISON

HemaSphere, 2022-06, Vol.6 (Suppl), p.789-790

2022

Link zum Volltext

Verfügbarkeit prüfen

PB2014: TECLISTAMAB VS SELINEXOR‐DEXAMETHASONE IN PATIENTS WITH TRIPLE‐CLASS EXPOSED RELAPSED/REFRACTORY MULTIPLE MYELOMA: A MATCHING‐ADJUSTED INDIRECT COMPARISON

HemaSphere, 2022-06, Vol.6 (Suppl), p.1885-1886

2022

Link zum Volltext

Verfügbarkeit prüfen

P922: HEALTH‐RELATED QUALITY OF LIFE WITH TECLISTAMAB, A B‐CELL MATURATION ANTIGEN X CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA FROM MAJESTEC‐1

HemaSphere, 2022-06, Vol.6 (Suppl), p.812-813

2022

Link zum Volltext

Verfügbarkeit prüfen

S188: TECLISTAMAB IN COMBINATION WITH DARATUMUMAB, A NOVEL, IMMUNOTHERAPY‐BASED APPROACH FOR THE TREATMENT OF RELAPSED/REFRACTORY MULTIPLE MYELOMA: UPDATED PHASE 1B RESULTS

HemaSphere, 2022-06, Vol.6, p.89-90

2022

Link zum Volltext

Verfügbarkeit prüfen

Extramedullary multiple myeloma escapes the effect of thalidomide

Haematologica (Roma), 2004-07, Vol.89 (7), p.832

2004

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 149

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(147)
Mit Volltextzugriff
(145)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(67)
Science & Technology
(67)
Humans
(64)
Hematology
(56)
Multiple Myeloma
(44)
Oncology
(43)
Female
(39)
Aged
(36)
Male
(36)
Middle Aged
(32)
Biological And Medical Sciences
(30)
Medical Sciences
(30)
Multiple Myeloma - Drug Therapy
(25)
Adult
(24)
Prognosis
(23)
Immunodeficiencies. Immunoglobulinopathies
(20)
Immunoglobulinopathies
(20)
Immunopathology
(20)
Transplantation
(20)
Multiple Myeloma - Therapy
(19)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Leukemia
(19)
Hemasphere
(18)
Blood
(16)
Bone Marrow Transplantation
(14)
Clinical Lymphoma, Myeloma And Leukemia
(13)
Haematologica
(11)
Journal Of Clinical Oncology
(9)
British Journal Of Haematology
(7)
Value In Health
(5)
Annals Of Oncology
(4)

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

A randomized phase III study of carfilzomib vs low-dose corticosteroids with optional cyclophosphamide in relapsed and refractory multiple myeloma (FOCUS)

Carfilzomib-dexamethasone vs bortezomib-dexamethasone in relapsed or refractory multiple myeloma by cytogenetic risk in the phase 3 study ENDEAVOR

Prognostic value of antigen expression in multiple myeloma: a PETHEMA/GEM study on 1265 patients enrolled in four consecutive clinical trials

Impact of prior treatment on patients with relapsed multiple myeloma treated with carfilzomib and dexamethasone vs bortezomib and dexamethasone in the phase 3 ENDEAVOR study

Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study

Bortezomib and thalidomide maintenance after stem cell transplantation for multiple myeloma: a PETHEMA/GEM trial

Analytical and clinical validation of a novel in-house deep-sequencing method for minimal residual disease monitoring in a phase II trial for multiple myeloma

Pathogenesis and treatment of renal failure in multiple myeloma

A multiparameter flow cytometry immunophenotypic algorithm for the identification of newly diagnosed symptomatic myeloma with an MGUS-like signature and long-term disease control

Prognostic and biological implications of genetic abnormalities in multiple myeloma undergoing autologous stem cell transplantation : t(4;14) is the most relevant adverse prognostic factor, whereas RB deletion as a unique abnormality is not associated with adverse prognosis

Pathogenesis and progression of monoclonal gammopathy of undetermined significance

Pattern of relapse and progression after autologous SCT as upfront treatment for multiple myeloma

Absence of spontaneous response improvement beyond day +100 after autologous stem cell transplantation in multiple myeloma

Clinical significance of CD81 expression by clonal plasma cells in high-risk smoldering and symptomatic multiple myeloma patients

At-home autologous stem cell transplantation in multiple myeloma with and without G-CSF administration: a comparative study

Allogeneic hematopoietic SCT in multiple myeloma: long-term results from a single institution

Carfilzomib-lenalidomide-dexamethasone vs lenalidomide-dexamethasone in relapsed multiple myeloma by previous treatment

Prognostic factors for multiple myeloma in the era of novel agents

Diagnosis, treatment, and response assessment in solitary plasmacytoma: updated recommendations from a European Expert Panel

Serial intestinal endoscopic examinations of patients with persistent diarrhea after allo-SCT

P898: COMPARISON OF TECLISTAMAB WITH BELANTAMAB MAFODOTIN IN PATIENTS WITH TRIPLE‐CLASS EXPOSED RELAPSED/REFRACTORY MULTIPLE MYELOMA USING MATCHING‐ADJUSTED INDIRECT TREATMENT COMPARISON

PB2014: TECLISTAMAB VS SELINEXOR‐DEXAMETHASONE IN PATIENTS WITH TRIPLE‐CLASS EXPOSED RELAPSED/REFRACTORY MULTIPLE MYELOMA: A MATCHING‐ADJUSTED INDIRECT COMPARISON

P922: HEALTH‐RELATED QUALITY OF LIFE WITH TECLISTAMAB, A B‐CELL MATURATION ANTIGEN X CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA FROM MAJESTEC‐1

S188: TECLISTAMAB IN COMBINATION WITH DARATUMUMAB, A NOVEL, IMMUNOTHERAPY‐BASED APPROACH FOR THE TREATMENT OF RELAPSED/REFRACTORY MULTIPLE MYELOMA: UPDATED PHASE 1B RESULTS

Extramedullary multiple myeloma escapes the effect of thalidomide

Suchergebnisse filtern